NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Lixte Biotechnology's Participation in DealFlow Discovery Conference and LB-100 Development
TL;DR
Lixte Biotechnology's CEO will meet investors at the DealFlow conference, potentially gaining funding advantages for advancing their first-in-class cancer drug LB-100 through clinical trials.
Lixte Biotechnology is developing LB-100, a protein phosphatase 2A inhibitor that enhances cancer treatments through clinical trials for ovarian and colon cancers.
Lixte's LB-100 drug could improve cancer treatment outcomes by enhancing existing therapies, potentially making tomorrow better for patients with difficult-to-treat cancers.
Lixte Biotechnology pioneers activation lethality, a new cancer treatment approach using their first-in-class PP2A inhibitor LB-100 to potentially revolutionize cancer therapy.
Found this article helpful?
Share it with your network and spread the knowledge!
Lixte Biotechnology Holdings announced it will participate in the DealFlow Discovery Conference on January 28-29, 2026, in Atlantic City, New Jersey, where CEO Geordan Pursglove will conduct one-on-one meetings with investors.
LB-100 is Lixte's first-in-class inhibitor of protein phosphatase 2A (PP2A), which is well-tolerated in cancer patients at doses associated with anti-cancer activity and has potential to significantly enhance chemotherapies and immunotherapies.
Lixte Biotechnology Holdings is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing/commercializing cancer therapies.
Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer, and the company continues advancing LB-100 through clinical development.
Activation lethality is described as an entirely new field of cancer biology that LB-100 is part of, representing a pioneering effort and new treatment paradigm covered by Lixte's comprehensive patent portfolio.
The latest news and updates relating to LIXT are available in the company's newsroom at http://ibn.fm/LIXT, and the full press release can be viewed at https://ibn.fm/F1dlA.
The DealFlow Discovery Conference is an event where Lixte's CEO will conduct one-on-one meetings with investors as the company continues advancing LB-100 through clinical development.
InvestorWire is a specialized communications platform that published this content, providing wire-grade press release syndication and distribution services as part of the IBN (InvestorBrandNetwork) portfolio of brands.
Curated from InvestorBrandNetwork (IBN)
